title: Atypical antipsychotic therapy and hyperlipidemia: a review.
abstract: Ziprasidone (Geodon), risperidone (Risperdal), and aripiprazole (Abilify) appear to be associated with a relatively low risk for hyperlipidemia, whereas quetiapine (Seroquel), olanzapine (Zyprexa), and clozapine (Clozaril) are associated with a relatively high risk for hyperlipidemia. Possible underlying causes of lipid dysregulation include weight gain, dietary changes, and glucose intolerance. Given the multiple cardiovascular risk factors reported for patients with schizophrenia, great care must be exercised to minimize the additional risk for hyperlipidemia when choosing antipsychotic therapy. It is recommended that a lipid panel be obtained at baseline for all patients with schizophrenia and annually thereafter for patients taking relatively low-risk agents or quarterly thereafter for patients taking relatively high-risk agents. Patients with persistent dyslipidemia should be referred for lipid-lowering therapy or switched to a less lipid-enhancing antipsychotic agent.
authors.affiliation: GlaxoSmithKline, Upper Providence, Pennsylvania, USA.
authors.forename: Carol E
authors.initials: CE
authors.lastname: Koro
authors.forename: Jonathan M
authors.initials: JM
authors.lastname: Meyer
mesh_terms: D014150:Antipsychotic Agents / Q000009:adverse effects* / Q000097:blood* / Q000627:therapeutic use; D016903:Drug Monitoring / Q000379:methods; D006801:Humans; D006949:Hyperlipidemias / Q000097:blood* / Q000139:chemically induced*; D012559:Schizophrenia / Q000097:blood / Q000188:drug therapy
chemical_list: D014150:Antipsychotic Agents